Effect of Tafamidis on Serum Transthyretin Levels in Non-Trial Patients With Transthyretin Amyloid Cardiomyopathy
Authors:
Open Access
- 19 October 2021
- journal article
- research article
- Published by Elsevier in JACC: Cardiooncology
- Vol. 3 (4) , 580-586
Abstract
No abstract availableKeywords
Funding Information
- Ionis Pharmaceuticals
- Pfizer
- GlaxoSmithKline
- Alnylam Pharmaceuticals
- GE Healthcare
This publication has 14 references indexed in Scilit:
- Stabilization of Cardiac Function With Diflunisal in Transthyretin (ATTR) Cardiac AmyloidosisJournal of Cardiac Failure, 2019
- Transthyretin Stabilization by AG10 in Symptomatic Transthyretin Amyloid CardiomyopathyJACC, 2019
- Tafamidis for transthyretin amyloid cardiomyopathy: the solution or just the beginning of the end?European Heart Journal, 2019
- Transthyretin Aggregation Pathway toward the Formation of Distinct Cytotoxic OligomersScientific Reports, 2019
- Tafamidis Treatment for Patients with Transthyretin Amyloid CardiomyopathyNew England Journal of Medicine, 2018
- Enthalpy-Driven Stabilization of Transthyretin by AG10 Mimics a Naturally Occurring Genetic Variant That Protects from Transthyretin AmyloidosisJournal of Medicinal Chemistry, 2018
- Tafamidis in Transthyretin Amyloid CardiomyopathyCirculation: Heart Failure, 2015
- Repurposing Diflunisal for Familial Amyloid PolyneuropathyJAMA, 2013
- Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascadeProceedings of the National Academy of Sciences, 2012
- Diflunisal Analogues Stabilize the Native State of Transthyretin. Potent Inhibition of AmyloidogenesisJournal of Medicinal Chemistry, 2003